Tolerance and Effect on Intraocular Pressure After Administration of SYL040012
Summary
The purpose of this study is to determine whether SYL040012 is safe for the treatment of ocular hypertension and glaucoma.
Study Design
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Conditions
Ocular Hypertension
Intervention
SYL040012
Location
Clínica Universitaria de Navarra
Pamplona
Navarra
Spain
31008
Status
Recruiting
Source
Sylentis, S.A.
Results (where available)
Links
- Source: http://clinicaltrials.gov/show/NCT00990743
- Information obtained from ClinicalTrials.gov on July 15, 2010
Published on BioPortfolio: 2014-08-27T03:18:51-0400
Clinical Trials
SYL040012, Treatment for Open Angle Glaucoma
The purpose of this double-masked, randomized, controlled study is to assess the safety and ocular hypotensive efficacy of four different doses of SYL040012 (bamosiran) eye drops compared ...
Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension
To evaluate if preservative free cosopt is well tolerated in patients with Open angle glaucoma (OAG) or Ocular hypertension (OH) with dry eyes.
A Three Part Study of MGV354 in Ocular Hypertension or Glaucoma
The purpose of this study is to determine if the clinical profile of topical-ocular MGV354 merits further development for the indication of lowering intraocular pressure (IOP).
The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanopr...
A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom
Study PhXA41 for its non-inferiority compared with timolol in lowering intra-ocular pressure
PubMed Articles
Mouse model of ocular hypertension with retinal ganglion cell degeneration.
Ocular hypertension is a primary risk factor for glaucoma and results in retinal ganglion cell (RGC) degeneration. Current animal models of glaucoma lack severe RGC cell death as seen in glaucoma, mak...
LATE-ONSET OCULAR HYPERTENSION AFTER VITRECTOMY: A Multicenter Study of 6,048 Eyes.
To determine the incidence and risk factors for late-onset ocular hypertension (LOH) after vitrectomy.
Chronic ocular hypertension in rabbits induced by limbal buckling.
To establish a rabbit model of chronic ocular hypertension (OHT) by limbal buckling.
The objective was to assess the long-term effect of treatment with latanoprost on ocular development and safety in pediatric patients with glaucoma and ocular hypertension.
OCULAR HYPERTENSION AFTER INTRAVITREAL INJECTION OF 2-MG TRIAMCINOLONE.
To report the incidence and course of ocular hypertension after intravitreal injection of 2-mg triamcinolone acetonide (IVT).
Medical and Biotech [MESH] Definitions
Paraneoplastic Syndromes, Ocular
Ocular manifestations secondary to various NEOPLASMS in which antibodies to antigens of the primary tumor cross-react with ocular antigens. This autoimmune response often leads to visual loss and other ocular dysfunctions.
Ocular Hypertension
A condition in which the intraocular pressure is elevated above normal and which may lead to glaucoma.
Accommodation, Ocular
The dioptric adjustment of the EYE (to attain maximal sharpness of retinal imagery for an object of regard) referring to the ability, to the mechanism, or to the process. Ocular accommodation is the effecting of refractive changes by changes in the shape of the CRYSTALLINE LENS. Loosely, it refers to ocular adjustments for VISION, OCULAR at various distances. (Cline et al., Dictionary of Visual Science, 4th ed)
Travoprost
A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
Bimatoprost
A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.
